Q2 2023

Filed Aug 4, 2023 · 10-Q · 35 days after period end · 0001062822-23-000047

Q2 2023 · 10-Q

Revenue

$291.00K

— vs Q2 2022

Net Income

-$44.90M

N/M vs Q2 2022

EPS Diluted

-$0.22

no prior Q2 2022 on file

Operating Income-$44,240,000N/M

Operating Cash Flow

Same quarter

Metric	Q2 2023	Q2 2022	Q2 2021	Q2 2016
Revenue	$291.00K	$0.00	$0.00	$12.09M
Net Income	-$44.90M	-$24.59M	-$18.07M	-$35.06M
EPS Diluted	-$0.22	—	—	-$0.33

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR